surpass 6 tirzepatide Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Flow of Participants in the

Although these medications dont interact, this doesnt mean there arent possible risks to taking them together

Drawing and injecting with the same syringe minimizes waste, requires only one needle puncture of the vial stopper, and keeps the process simple

This visit is covered by most insurance plans

1 Results from the STEER study showed that treatment with semaglutide 2.4 mg resulted in a significantly greater risk reduction for heart attack, stroke, cardiovascular-related death or death from any cause compared to tirzepatide

For some patients that is easier to live with

In ACHIEVE-3, orforglipron 36 mg produced 9.2% weight loss in T2D at 52 weeks